期刊文献+

Comparison of clinical features and outcomes of proliferative,fibrotic,and mixed subtypes of IgG4-related disease:A retrospective cohort study

原文传递
导出
摘要 Background:Immunoglobulin G4-related disease(IgG4-RD)is a recently recognized immune-mediated disorder that can affect almost any organ in the human body.IgG4-RD can be categorized into proliferative and fibrotic subtypes based on patients’clinicopathological characteristics.This study aimed to compare the clinical manifestations,laboratory findings,and treatment outcomes of IgG4-RD among different subtypes.Methods:We prospectively enrolled 622 patients with newly diagnosed IgG4-RD at Peking Union Medical College Hospital from March 2011 to August 2021.The patients were divided into three groups according to their clinicopathological characteristics:proliferative,fibrotic,and mixed subtypes.We compared demographic features,clinical manifestations,organ involvement,laboratory tests,and treatment agents across three subtypes.We then assessed the differences in treatment outcomes among 448 patients receiving glucocorticoids alone or in combination with immunosuppressants.Moreover,risk factors of relapse were revealed by applying the univariate and multivariate Cox regression analysis.Results:We classified the 622 patients into three groups consisting of 470 proliferative patients,55 fibrotic patients,and 97 mixed patients,respectively.We found that gender distribution,age,disease duration,and frequency of allergy history were significantly different among subgroups.In terms of organ involvement,submandibular and lacrimal glands were frequently involved in the proliferative subtype,while retroperitoneum was the most commonly involved site in both fibrotic subtype and mixed subtype.The comparison of laboratory tests revealed that eosinophils(P=0.010),total IgE(P=0.006),high-sensitivity C-reactive protein(P<0.001),erythrocyte sedimentation rate(P<0.001),complement C4(P<0.001),IgG(P=0.001),IgG1(P<0.001),IgG4(P<0.001),and IgA(P<0.001),at baseline were significantly different among three subtypes.Compared with proliferative and mixed subtypes,the fibrotic subtype showed the lowest rate of relapse(log-rank P=0.014).Conclusions:Our study revealed the differences in demographic characteristics,clinical manifestations,organ involvement,laboratory tests,treatment agents,and outcomes across proliferative,fibrotic,and mixed subtypes in the retrospective cohort study.Given significant differences in relapse-free survival among the three subtypes,treatment regimens,and follow-up frequency should be considered separately according to different subtypes.Trial Registration:ClinicalTrials.gov,NCT01670695.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2024年第3期303-311,共9页 中华医学杂志(英文版)
基金 supported by the National Key Research and Development Program of China(No.2022YFC2703104) the National Natural Science Foundation of China(Nos.82071839,82271848) CAMS Innovation Fund for Medical Sciences(Nos.CIFMS 2021-1-I2M-003,2022-I2M-C&T-B-005) National High Level Hospital Clinical Research Funding(Nos.2022-PUMCH-A-041,2022-PUMCH-C-006,2022-PUMCH-B-013) Open Research Fund of State Key Laboratory of Environmental Chemistry and Ecotoxicology(No.KF2021-15)
作者简介 Linyi Peng,contributed equally to this work;Xinlu Zhang,contributed equally to this work;Correspondence to:Wen Zhang,Department of Rheumatology and Clinical Immunology,Peking Union Medical College Hospital,National Clinical Research Center for Dermatologic and Immunologic Diseases,State Key Laboratory of Complex Severe and Rare Diseases,The Ministry of Education Key Laboratory,No.1 Shuaifuyuan,Beijing 100730,China,E-Mail:zhangwen91@sina.com
  • 相关文献

参考文献2

二级参考文献22

  • 1Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67:1688-99. doi: 10.1002/art.39132.
  • 2Stone JH, Zen Y, Deshpande V. [gG4-related disease. N Engl J Med 2012;366:539-51. doi: 10.1056/NEJMral 104650.
  • 3Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et aL High serum lgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 2001;344:732-8. doi: 10.1056/ NEJM200103083441005.
  • 4Della-Torre E, Lanzillotta M, Doglioni C. Immunology of lgG4-re|ated disease. Clin Exp |mmunol 2015;181:191-206. doi: I0.1 I11/cei.12641.
  • 5Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for lgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012;22:21-30. doi: 10.3109/s I 0165 -011-0571 -z.
  • 6Lin W, Jin L, Chen H, Wu Q, Fei Y, Zheng W, et al. B cell subsets and dysfunction of regulatory B cells in lgG4-related diseases andprimary Sj6gren's syndrome: The similarities and differences. Arthritis Res Ther 2014;16:R 118. doi: I 0.1186/ar4571.
  • 7Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et aL Plasmablasts as a biomarker for lgG4-related disease, independent of serum lgG4 concentrations. Ann Rheum Dis 2015;74:190-5. doi: 10.1 ! 36/annrheumdis-2014-205233.
  • 8Kamisawa T, Zen Y, Pillai S, Stone JH. lgG4-related disease. Lancet 2015;385:1460-71. doi: 10.1016/S0140-6736( 14)60720-0.
  • 9Guma M, Firestein GS, lgG4-related diseases. Best Pract Res Clin Rheumatol 2012;26:425-38. doi: 10.1016/j.berh.2012.07.001.
  • 10Chen H, Lin W, Wang Q, Wu Q, Wang L, Fei Y, et al. lgG4-related disease in a Chinese cohort: A prospective study. Scand J Rheumatol 2014;43:70-4. doi: 10.3109/03009742.2013.822094.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部